Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis?

SERGEY MOISEEV, ANASTASIIA ZYKOVA, NIKOLAY BULANOV, EVGENY GITEL, PAVEL NOVIKOV, MAYRA BULANOVA, ANDREAS KRONBICHLER and DAVID JAYNE
The Journal of Rheumatology April 2020, 47 (4) 636-638; DOI: https://doi.org/10.3899/jrheum.191082
SERGEY MOISEEV
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, and Lomonosov Moscow State University;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for SERGEY MOISEEV
  • For correspondence: avt420034@yahoo.com
ANASTASIIA ZYKOVA
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, and Lomonosov Moscow State University, Moscow, Russia;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ANASTASIIA ZYKOVA
NIKOLAY BULANOV
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for NIKOLAY BULANOV
EVGENY GITEL
Sechenov First Moscow State Medical University;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for EVGENY GITEL
PAVEL NOVIKOV
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAYRA BULANOVA
Vladimir Regional Clinical Hospital, Vladimir, Russia;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREAS KRONBICHLER
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria;
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ANDREAS KRONBICHLER
DAVID JAYNE
Department of Medicine, University of Cambridge, Cambridge, UK.
MD, FRCP, FRCPE, FmedSci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAV) form a group of necrotizing small-vessel vasculitides characterized by the presence of ANCA against either proteinase 3 (PR3) or myeloperoxidase (MPO). ANCA have a key role in the pathogenesis of AAV, inducing excessive activation of neutrophils, which results in injury to small vessels1. ANCA can target other neutrophil-derived molecules, among them lysosome-associated membrane glycoprotein 2 (LAMP-2).

LAMP-2 is a glycosylated membrane protein expressed in lysosomes and on the surface of neutrophils and glomerular cells2. Antibodies against LAMP-2 were originally detected in cases with active AAV and pauci-immune crescentic glomerulonephritis3. Subsequent experimental studies showed that passive immunization with rabbit IgG to recombinant LAMP-2 or active immunization with recombinant FimH (a bacterial adhesion protein present in gram-negative bacteria and sharing 1 epitope of LAMP-2) can induce pauciimmune crescentic glomerulonephritis in rats, thus supporting the pathogenicity of anti–LAMP-2 antibodies4.

Patients with active AAV defined as a Birmingham Vasculitis Activity Score (BVAS) of ≥ 3 were included in our study. Serum concentration of anti–LAMP-2 antibodies was determined using a commercial ELISA kit according to the instructions of manufacturer (PD-H07441, Puda Scientific). Seropositivity for LAMP-2 antibodies was defined as a value higher than the upper reference limit of the control group5.

Fifty-nine patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis were enrolled. The median BVAS was 16.5 at the time of testing (Table 1). Twenty-three of 35 newly diagnosed patients were sampled 4–6 weeks after initiation of immunosuppressive therapy, whereas 12 were treatment-naive at the time of testing. All patients with relapsing AAV received maintenance therapy. In 28 patients, repeated samples were obtained during stable remission after a median of 16 months. Thirty-six healthy volunteers (9 men and 27 women, average age 55.7 ± 12.4 yrs) comprised the control group. Using data from the control group, the upper reference level of anti–LAMP-2 antibodies was defined as 48.9 ng/ml. The study was approved by the Sechenov First Moscow University Institutional Review Board (IRB approval number 06-104). All patients gave informed consent for participation in our research study.

View this table:
  • View inline
  • View popup
Table 1.

Demographic and clinical features of 59 patients with AAV.

In patients with AAV, the median concentration of anti–LAMP-2 antibodies was higher than in the control group: 42.1 ng/ml (95% CI 39.7–45.9) and 37.1 ng/ml (95% CI 35.7–39.2), respectively (p < 0.001). However, only 10.1% tested positive for these antibodies (Figure 1). Most of them had newly diagnosed AAV with BVAS score of 12 to 26, and were classified as GPA. Of the 6 positive patients, 5 showed only modestly increased LAMP-2 antibodies titers. There was no correlation between the concentration of anti–LAMP-2 antibodies and BVAS score (r = 0.038, p = 0.772).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Concentration of anti–LAMP-2 antibodies in patients with AAV and in the control group. Treatment-naive patients marked in gray. LAMP-2: lysosome-associated membrane glycoprotein 2; AAV: antineutrophil cytoplasmic antibody–associated vasculitides.

All patients with anti–LAMP-2 antibodies were seropositive for PR3-ANCA. Nevertheless, median concentrations of anti–LAMP-2 antibodies were similar in patients with PR3-ANCA and MPO-ANCA [41.4 (35.5, 43.4) and 44.2 (38.3, 46.1), respectively; p = 0.884]. Moreover, anti–LAMP-2 antibodies were found in only 1 of 12 patients (8.3%) with a new diagnosis of AAV and no history of any immunosuppressive treatment. At remission, concentration of anti–LAMP-2 antibodies decreased below reference value in all 6 who were seropositive, whereas it increased slightly above the reference value in 1 seronegative patient. The median concentration of LAMP-2 antibodies did not change following achievement of remission (44.0 and 39.8 ng/ml; p = 0.079).

Our findings suggest that anti–LAMP-2 antibodies are not useful for clinical evaluation of patients with AAV and play a minor role, if any, in disease pathogenesis. On the contrary, Kain, et al detected anti–LAMP-2 antibodies in 80–91% of 64 patients with newly diagnosed AAV from 3 European centers and showed high concordance (80.5%) among the 3 assays (ELISA, Western blot, and an indirect immunofluorescence assay)6. Anti–LAMP-2 antibodies rapidly became undetectable after the initiation of immunosuppressive treatment and frequently became detectable again during clinical relapse6. In line with our results, Roth, et al reported anti–LAMP-2 reactivity in 21% of 329 ANCA-positive patients, in 29% of 104 ANCA-negative patients, and in 16% of 104 patients with a FimH-positive urinary tract infection7. Anti–LAMP-2 antibodies titers were usually low, and did not correlate to disease activity scores7.

Methodologic issues may be responsible for the conflicting results of our and previous studies8. Kain and Rees suggested that the existing controversies will be resolved once robust “clinical grade” assays have been developed2. Thus far, no such efforts have been undertaken. The results published by Roth and colleagues and ours clearly argue against a role of LAMP-2 in AAV7. The fate of non-reproduced published findings is well established, with confirmation in below 50% of the scientific reports9. This number may be even more pronounced, because reports of positive findings are published more often and more quickly compared to negative data10.

Our study has some limitations. The number of patients was relatively small. However, we do not expect that our findings would have been different with a larger sample size given the very low prevalence of anti–LAMP-2 reactivity.

Footnotes

  • The study was supported by a grant from Sechenov University. Dr. Kronbichler has received an unrestricted grant from the Austrian Society of Rheumatology.

REFERENCES

  1. 1.↵
    1. Nakazawa D,
    2. Masuda S,
    3. Tomaru U,
    4. Ishizu A
    . Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15:91–101.
    OpenUrl
  2. 2.↵
    1. Kain R,
    2. Rees AJ
    . What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? Curr Opin Rheumatol 2013;25:26–34.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kain R,
    2. Matsui K,
    3. Exner M,
    4. Binder S,
    5. Schaffner G,
    6. Sommer EM,
    7. et al.
    A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995;181:585–97.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kain R,
    2. Exner M,
    3. Brandes R,
    4. Ziebermayr R,
    5. Cunningham D,
    6. Alderson CA,
    7. et al.
    Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14:1088–96.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Sasse EA
    . Determination of reference intervals in the clinical laboratory using the proposed guideline National Committee for Clinical Laboratory Standards C28-P. Arch Pathol Lab Med 1992;116:710–3.
    OpenUrlPubMed
  6. 6.↵
    1. Kain R,
    2. Tadema H,
    3. McKinney EF,
    4. Benharkou A,
    5. Brandes R,
    6. Peschel A,
    7. et al.
    High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012;23:556–66.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Roth AJ,
    2. Brown MC,
    3. Smith RN,
    4. Badhwar AK,
    5. Parente O,
    6. Chung H,
    7. et al.
    Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012;23:545–55.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Fervenza FC,
    2. Specks U
    . Vasculitis: Will LAMP enlighten us about ANCA-associated vasculitis? Nat Rev Nephrol 2012;8:318–20.
    OpenUrlPubMed
  9. 9.↵
    1. Begley CG,
    2. Ellis LM
    . Drug development: raise standards for preclinical cancer research. Nature 2012;483:531–3.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Hopewell S,
    2. Loudon K,
    3. Clarke MJ,
    4. Oxman AD,
    5. Dickersin K
    . Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009;(1):MR000006.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 4
1 Apr 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis?
SERGEY MOISEEV, ANASTASIIA ZYKOVA, NIKOLAY BULANOV, EVGENY GITEL, PAVEL NOVIKOV, MAYRA BULANOVA, ANDREAS KRONBICHLER, DAVID JAYNE
The Journal of Rheumatology Apr 2020, 47 (4) 636-638; DOI: 10.3899/jrheum.191082

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis?
SERGEY MOISEEV, ANASTASIIA ZYKOVA, NIKOLAY BULANOV, EVGENY GITEL, PAVEL NOVIKOV, MAYRA BULANOVA, ANDREAS KRONBICHLER, DAVID JAYNE
The Journal of Rheumatology Apr 2020, 47 (4) 636-638; DOI: 10.3899/jrheum.191082
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
  • High-Sensitivity Cardiac Troponin T as a Marker to Improve Cardiovascular Disease Risk Assessment Among Patients With Rheumatoid Arthritis
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire